2. Search Result
Search Result
Results for "

urinary incontinence

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

1

Peptides

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-116408A
    Propiverine hydrochloride

    		mAChR Calcium Channel Neurological Disease
    Propiverine hydrochloride is a bladder spasmolytic with calcium antagonistic and anticholinergic properties. Propiverine hydrochloride can be used for the research of overactive blaqdder and urinary incontinence .
    Propiverine hydrochloride
  • HY-117071
    Dabuzalgron

    Ro 115-1240

    		 Adrenergic Receptor Apoptosis Cardiovascular Disease Endocrinology
    Dabuzalgron (Ro 115-1240) is an orally active and selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function .
    Dabuzalgron
  • HY-19933
    Vibegron

    MK-4618

    		 Adrenergic Receptor Others
    Vibegron (MK-4618) is a potent, highly selective and orally active β3-adrenoceptor agonist (EC50=1.1 nM). Vibegron can be used for severe urgency urinary incontinence related to overactive bladder .
    Vibegron
  • HY-U00357
    Urinary Incontinence-Targeting Compound 1

    		Others Neurological Disease
    Urinary Incontinence-Targeting Compound 1 is a sulfonanilide derivative, used in the research of urinary incontinence.
    Urinary Incontinence-Targeting Compound 1
  • HY-120322
    MK-0969

    		mAChR Others
    MK-0969 is a M3 antagonist. MK-0969 can be used for research about chronic obstructive pulmonary disease and urinary incontinence .
    MK-0969
  • HY-16489
    Terodiline

    		Potassium Channel mAChR Calcium Channel Metabolic Disease
    Terodiline, an antispasmodic agent, blocks hERG current with the IC50 of 375 nM. Terodiline has both anticholinergic and calcium antagonist properties, and effectively reduces abnormal bladder contractions caused by detrusor instability. Terodiline can be used for the research of urinary incontinence .
    Terodiline
  • HY-117071A
    Dabuzalgron hydrochloride

    Ro 115-1240 hydrochloride

    		 Adrenergic Receptor Apoptosis Cardiovascular Disease Endocrinology
    Dabuzalgron (Ro 115-1240) hydrochloride is an orally active and selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron hydrochloride protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function .
    Dabuzalgron hydrochloride
  • HY-119103
    PF-03246799

    		5-HT Receptor Neurological Disease
    PF-03246799 (PF-3246799) is a potent and selective 5-HT2C receptor agonist with an EC50 of 190 nM and a Ki of 160 nM. PF-03246799 shows selectivity for 5-HT2C over 5-HT2A and 5-HT2B receptors. PF-03246799 has the potential for stress urinary incontinence (SUI) research .
    PF-03246799
  • HY-118064
    (R)-Thionisoxetine

    LY-368975

    		 Others Neurological Disease
    (R)-Thionisoxetine is a potent and selective inhibitor of central and peripheral norepinephrine (NE) uptake. (R)-thionisoxetine prevented hypothalamic NE depletion by 6-hydroxydopamine with an ED50 of 0.21 mg/kg. (R)-Thionisoxetine can be used for the research of a variety of diseases including depression and urinary incontinence .
    (R)-Thionisoxetine
  • HY-118064A
    (R)-Thionisoxetine hydrochloride

    LY-368975 hydrochloride

    		 Others Neurological Disease
    (R)-Thionisoxetine hydrochloride (LY-368975 hydrochloride) is a potent and selective central and peripheral norepinephrine (NE) uptake inhibitor. (R)-Thionisoxetine hydrochloride prevents 6-hydroxydopamine-induced hypothalamic NE depletion with an ED50 of 0.21 mg/kg. (R)-Thionisoxetine hydrochloride can be used in the study of a variety of diseases, including depression and urinary incontinence .
    (R)-Thionisoxetine hydrochloride
  • HY-116567
    OPC-51803

    		Vasopressin Receptor Metabolic Disease
    OPC-51803 is an orally active nonpeptide vasopressin V2 receptor agonist. OPC-51803 can be used for the research of micturition disorders that result in frequent micturition, such as that from polyuria, nocturnal polyuria, and some kinds of urinary incontinence .
    OPC-51803
  • HY-16489A
    Terodiline hydrochloride

    		mAChR Calcium Channel Neurological Disease
    Terodiline hydrochloride is an M1-selective muscarinic receptor (mAChR) antagonist with Kbs of 15, 160, 280, and 198 nM in rabbit vas deferens (M1), atria (M2), bladder (M3) and ileal muscle (M3), respectively. Terodiline hydrochloride also is a Ca 2+ blocker. Terodiline hydrochloride acts as a treatment for urinary frequency and urge incontinence .
    Terodiline hydrochloride
  • HY-148252
    ADRA1D receptor antagonist 1 free base

    		Adrenergic Receptor Endocrinology
    ADRA1D receptor antagonist 1 (free base) (compound (R)-9s) is an orally active, potent and selective human α1D-adrenoceptor (α1D-AR) antagonist (Ki=1.6 nM). ADRA1D receptor antagonist 1 (free base) dose-dependently inhibits bladder contraction with an IC30 value of 15 nM. ADRA1D receptor antagonist 1 (free base) can be used in studies of overactive bladder disorders such as urinary urgency, frequency and incontinence.
    ADRA1D receptor antagonist 1 free base
  • HY-116408AS
    Propiverine-d7 hydrochloride

    		Isotope-Labeled Compounds mAChR Calcium Channel Neurological Disease
    Propiverine-d7 (hydrochloride) is the deuterium labeled Propiverine hydrochloride. Propiverine hydrochloride is a bladder spasmolytic with calcium antagonistic and anticholinergic properties. Propiverine hydrochloride can be used for the research of overactive blaqdder and urinary incontinence[1][2].
    Propiverine-d7 hydrochloride
  • HY-W101935
    N-Boc-D-Arg hydrochloride

    N-Boc-D-arginine hydrochloride

    		 Amino Acid Derivatives Others
    N-Boc-D-Arg hydrochloride (N-Boc-D-arginine hydrochloride) is an amino acid derivative with a Boc protecting group, which can be used to synthesize desmopressin with the effects of improving nocturia, urinary incontinence and enuresis .
    N-Boc-D-Arg hydrochloride
  • HY-126184
    Revatropate

    UK-112166

    		 mAChR Neurological Disease Inflammation/Immunology
    Revatropate is an antimuscarinic compound. Revatropate has a much greater inhibitory effect on M1 and M3 receptors than on the M2 subtype. Revatropate is used in the study of urge urinary incontinence and functional bowel disorders .
    Revatropate
  • HY-147383
    NS-8

    		Potassium Channel Endocrinology
    NS-8, a pyrrole derivative, activates the Ca 2+-sensitive k +-channel. NS-8 can suppress the micturition reflex by decreasing afferent pelvic nerve activity. NS-8 can be used in the research of urinary frequency and incontinence .
    NS-8
  • HY-B0267C
    (R)-Oxybutynin

    Aroxybutynin

    		 mAChR Neurological Disease
    (R)-Oxybutynin (Aroxybutynin) is the racemic isomer of Oxybutynin and an orally active muscarinic receptor antagonist. (R)-Oxybutynin has antispasmodic, antimuscarinic, and anticholinergic activities and competitively antagonizes carbachol-induced contractions. (R)-Oxybutynin can be used to study urinary incontinence caused by neurogenic bladder dysfunction .
    (R)-Oxybutynin
  • HY-B0267
    Oxybutynin

    		mAChR Potassium Channel Neurological Disease
    Oxybutynin is an anticholinergic agent, which inhibits vascular Kv channels in a concentration-dependent manner, with an IC50 of 11.51 μM . Oxybutynin is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Oxybutynin
  • HY-B0267A
    Oxybutynin chloride

    		mAChR Potassium Channel Neurological Disease
    Oxybutynin chloride is an oral active and competitive mAChR antagonist with Kis of 14.3 and 5.55 nM for specific [ 3H]NMS binding in the mouse bladder and cerebral cortex, respectively. Oxybutynin chloride inhibits vascular Kv channels in a manner independent of anticholinergic effect, with an IC50 value of 11.51 μM. Oxybutynin chloride reduces muscle spasm in the bladder and urinary tract, can be used in study of overactive bladder syndrome (OAB) . Oxybutynin (chloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Oxybutynin chloride
  • HY-B0267R
    Oxybutynin (Standard)

    		mAChR Potassium Channel Neurological Disease
    Oxybutynin (Standard) is the analytical standard of Oxybutynin. This product is intended for research and analytical applications. Oxybutynin is an anticholinergic agent, which inhibits vascular Kv channels in a concentration-dependent manner, with an IC50 of 11.51 μM . Oxybutynin is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Oxybutynin (Standard)
  • HY-B0461
    Trospium chloride

    		mAChR Neurological Disease
    Trospium chloride is an orally active, specific and competitive antagonist of muscarinic cholinergic receptors (mAChRs), with antimuscarinic activity. Trospium chloride binds to muscarinic receptors M1, M2 and M3 with high affinity, but not nicotinic, cholinergic receptors .
    Trospium chloride
  • HY-B0461R
    Trospium chloride (Standard)

    		mAChR Neurological Disease
    Trospium (chloride) (Standard) is the analytical standard of Trospium (chloride). This product is intended for research and analytical applications. Trospium chloride is an orally active, specific and competitive antagonist of muscarinic cholinergic receptors (mAChRs), with antimuscarinic activity. Trospium chloride binds to muscarinic receptors M1, M2 and M3 with high affinity, but not nicotinic, cholinergic receptors .
    Trospium chloride (Standard)
  • HY-116567A
    (S)-OPC-51803

    		Others Endocrinology
    (S)-OPC-51803 is an agonist of the vasopressin V2 receptor, with activity in suppressing nocturia and urinary incontinence. (S)-OPC-51803 was evaluated in terms of biological activity and showed a stronger V2 receptor agonist effect compared to its (R)-isomer. The use of (S)-OPC-51803 may improve the patient's ability to control nocturnal polyuria .
    (S)-OPC-51803
  • HY-123459
    Garomefrine (hydrochlorid)

    ABT-232; NS-49; PNO-49B

    		 Others Endocrinology
    Garomefrine hydrochlorid (ABT-232) is an α1A-adrenergic agonist with the potential to inhibit urinary incontinence. Garomefrine hydrochlorid showed the greatest contractility in pig nasal mucosal vessels. The biological activity of Garomefrine hydrochlorid has been shown to give it a competitive advantage compared to other drugs. The potency of Garomefrine hydrochlorid makes it a valuable research object in related research .
    Garomefrine (hydrochlorid)
  • HY-116771A
    CL 316243
    Maximum Cited Publications
    9 Publications Verification

    		 Adrenergic Receptor Metabolic Disease
    CL316243 is a highly potent selective β3-adrenoceptor agonist with a EC50 of 3 nM, but is an extremely poor to β1/2- receptors .CL316243 is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate . CL316243 has the potential for the treatment obesity, diabetes and urge urinary incontinence .
    CL 316243
  • HY-116771
    CL 316243 free acid
    Maximum Cited Publications
    9 Publications Verification

    		 Adrenergic Receptor Metabolic Disease
    CL316243 free acid is a highly potent selective β3-adrenoceptor agonist with a EC50 of 3 nM, but is an extremely poor to β1/2- receptors. CL316243 free acid is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate. CL316243 free acid has the potential for the treatment obesity, diabetes and urge urinary incontinence .
    CL 316243 free acid
  • HY-14790
    Esreboxetine

    (S,S)-Reboxetine

    		 Others Neurological Disease
    Esreboxetine ((S,S)-Reboxetine) is a selective norepinephrine reuptake inhibitor with activity in increasing urethral resistance. Esreboxetine has been reported to be effective in patients with stress urinary incontinence in a Phase IIa clinical study, achieving this effect by increasing urethral closure. The mechanism of action of esreboxetine involves inhibition of norepinephrine transporters in the central and peripheral nervous systems. The peripheral selectivity of esreboxetine helps it significantly increase urethral resistance without penetrating the brain .
    Esreboxetine
  • HY-B0406A
    Bethanechol chloride
    1 Publications Verification

    Carbamyl-β-methylcholine chloride

    		 mAChR Neurological Disease Cancer
    Bethanechol chloride (Carbamyl-β-methylcholine chloride), a parasympathomimetic agent, is a mAChR agonist that exerts its effects via directly stimulating the mAChR (M1, M2, M3, M4, and M5) of the parasympathetic nervous system .
    Bethanechol chloride
  • HY-B0406
    Bethanechol

    Carbamyl-β-methylcholine

    		 mAChR Neurological Disease Cancer
    Bethanechol (Carbamyl-β-methylcholine), a parasympathomimetic agent, is a mAChR agonist that exerts its effects via directly stimulating the mAChR (M1, M2, M3, M4, and M5) of the parasympathetic nervous system .
    Bethanechol
  • HY-137055
    PF-3774076

    		Others Others
    PF-3774076 is a highly central nervous system (CNS) penetrant, potent, and selective human α1A-adrenoceptor partial agonist. It exhibits good potency and selectivity in multiple binding and functional assays. PF-3774076 increases peak urethral pressure in anesthetized female dogs in a dose-dependent manner via a central mechanism. PF-3774076 affects both the proximal and distal portions of the urethra in vivo. These properties suggest that PF-3774076 may have significant benefit in the treatment of stress urinary incontinence (SUI) as a CNS-penetrant α1A receptor partial agonist. However, despite its partial agonism and selectivity for α1A receptors, PF-3774076 failed to provide adequate safety differences in in vivo models of cardiovascular function. This may be due to the simultaneous activation of both peripheral and central α1A receptors. These data suggest that while central α1A partial agonists may have significant benefit in the treatment of SUI, this class of agents may have difficulty achieving the desired urethral selectivity without affecting cardiovascular function.
    PF-3774076

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: